Cancer Genetics Inc (CGIX) 11.18 $CGIX
Cancer Genetics to Report First Quarter 2014 Results on Thursday, May 15, 2014
GlobeNewswire - Thu May 08, 7:01AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based diagnostics, announced today that it will report its financial results for the first quarter ended March 31, 2014 on Thursday, May 15, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Time.
Cancer Genetics Launches Genomic Tests for Follicular Lymphoma and Mantle Cell Lymphoma - Further Extends Unique Position in Targeted Testing of Hematologic Cancers
GlobeNewswire - Mon May 05, 8:42AM CDT
-- The Mantle-Cell and Follicular Lymphoma Tests Were Validated In Research Collaborations With Memorial Sloan Kettering and Have Been Successfully Licensed Under Both CLIA and New York State Regulations
Cancer Genetics to Promote FHACT(TM) Test for Cervical Cancer at American Congress of Obstetricians and Gynecologists' Annual Clinical Meeting
GlobeNewswire - Fri Apr 25, 9:42AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company", an emerging leader in DNA-based cancer diagnostics, will be participating in the Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG), being held April 26-30 at the McCormick Place Convention Center in Chicago, Illinois. ACOG is the premier gynecological conference in the U.S. The conference hosts more than 200 exhibitors, and features more than 400 original research posters and paper abstracts.
Pathway Genomics Adds Leading Genetic Counselors to Advisory Board
Business Wire - Thu Apr 17, 7:01AM CDT
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that it has added industry-leading genetic counselors Jill Davies, M.S., CCGC, and Elissa Levin, M.S., CGC, to its genetic advisory board.
Bio-Reference Laboratories, Inc. Announces That Robert Daber, Ph.D. Will Join Company as Director of R&D and Cancer Genetics
GlobeNewswire - Wed Apr 16, 7:30AM CDT
Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announced today that it has hired Robert Daber, Ph.D. to assume the dual role as Director of Research and Development and Director of Cancer Genetics at its Elmwood Park international headquarters. BRLI has been an industry leader in clinical diagnostics primarily as a result of its ongoing development of innovative testing based on new and emerging technology. Dr. Daber will take over leadership of this pioneering process along with his directorship of the cancer genetics program at BRLI.
Invitae's Multi-Gene Panels Can Provide Clinical Benefit to Patients Seeking Hereditary Cancer Risk Assessment
Business Wire - Mon Apr 14, 3:00PM CDT
Invitae Corporation, a genetic information company, today announced the publication of initial data from its research collaboration with Stanford University in the Journal of Clinical Oncology, published online on April 14. The study demonstrates that multi-gene hereditary cancer panels can offer comparable performance to traditional BRCA1/2 genetic testing and can provide additional clinical benefit to doctors and patients seeking cancer risk assessment.
Cancer Genetics CEO Moderates Panel Discussion With Thought Leaders in Biopharma at the BioNJ 2014 International BioPartnering Conference
GlobeNewswire - Thu Apr 10, 7:00AM CDT
-- Panna Sharma, CEO of Cancer Genetics, Is Moderating a Panel Entitled "Partnering for a Balanced Portfolio: Perspectives from Innovators, Partners, & Payers"
Cancer Genetics Announces Launch of CALR Mutation Analysis Test to Assist in Diagnosis of Acute Leukemias & Myeloproliferative Neoplasms
GlobeNewswire - Fri Apr 04, 7:17AM CDT
-- New Test Launch Extends CGI's Leadership in Genomic Testing for Blood Cancers
LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc.
Marketwire - Tue Apr 01, 8:03AM CDT
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company developing genomic-based oncology tests and services to enhance disease management and patient outcomes. The Company offers a wide-range of proprietary and non-proprietary tests to support patients during all aspects of their care, from initial diagnosis to prognosis, and determination of optimal treatment options. Oncology is moving towards categorizing cancers by their molecular signature rather than the location in the body, and there is a continuing need for wider access to diagnostic toolkits. Cancer Genetics collaborates with leading research institutions for biomarker development, with community hospitals to improve patient care, and with biotechnology and pharmaceutical companies to provide clinical trial services.
Five Star Quality Care (FVE) in Focus: Stock Tumbles 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:40AM CDT
Five Star Quality Care saw a big move last session, as the company’s shares fell nearly 10% on the day
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Mar 27, 9:56AM CDT
RedChip Companies, Inc. ("RedChip", an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature emerging growth companies on Fox Business nationwide on Thursday, March 27, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, March 29, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, March 30, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 30, 2014 at 3:30 p.m. HKT.
Cancer Genetics, Inc. Announces Fourth Quarter and Year-End 2013 Results, Provides Corporate Update
GlobeNewswire - Wed Mar 26, 3:01PM CDT
-- 72% Year-Over-Year Revenue Growth During Fourth Quarter 2013
Cancer Genetics to Report Fourth Quarter and Year-End 2013 Results on Wednesday, March 26, 2014
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company", an emerging leader in DNA-based diagnostics, announced today that it will report its results for the fourth quarter and year-end 2013 after the market close on Wednesday, March 26, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific.
Cancer Genetics Appoints Edward J. Sitar as Chief Financial Officer
GlobeNewswire - Mon Mar 17, 7:08AM CDT
Cancer Genetics (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, announced today that effective April 1, 2014, it has appointed Edward J. Sitar, CPA as Chief Financial Officer. Mr. Sitar will be responsible for all Corporate Finance and Accounting activities for Cancer Genetics.
Cancer Genetics Announces Compelling Diagnostic Sensitivity (99%) and Accuracy (93%) for Its Patent-Protected Genomic Kidney Cancer Test
GlobeNewswire - Wed Mar 05, 7:01AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" announced today the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required.
BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
Cancer Genetics, Inc. Adds Additional Kidney Cancer Patent to its Portfolio
GlobeNewswire - Wed Feb 26, 6:30AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company", an emerging leader in DNA-based diagnostics, today announced that the United States Patent and Trademark Office (USPTO) has allowed its patent claims related to the Company's proprietary methods for detecting the subtype of renal cortical neoplasm present in a patient sample. The patent application (14/078,726) is expected to obtain an issued patent number during the second quarter of 2014.
Cancer Genetics, Inc. Announces a New Breakthrough for Diagnosis and Prediction of Kidney Cancer Outcomes Using Its Proprietary Genomic Test
GlobeNewswire - Mon Feb 24, 6:30AM CST
--
Omnicare (OCR) Falls: Stock Goes Down 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:37AM CST
Omnicare Inc. (OCR) saw a big move last session. This stock, trading at a volatile range of $60.68–$64.54 in the past one-month time frame, showed a sharp decline yesterday at $60.98.
Cancer Genetics to Report First Quarter 2014 Results on Thursday, May 15, 2014
GlobeNewswire - Thu May 08, 7:01AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based diagnostics, announced today that it will report its financial results for the first quarter ended March 31, 2014 on Thursday, May 15, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Time. Cancer Genetics Launches Genomic Tests for Follicular Lymphoma and Mantle Cell Lymphoma - Further Extends Unique Position in Targeted Testing of Hematologic Cancers
GlobeNewswire - Mon May 05, 8:42AM CDT
-- The Mantle-Cell and Follicular Lymphoma Tests Were Validated In Research Collaborations With Memorial Sloan Kettering and Have Been Successfully Licensed Under Both CLIA and New York State Regulations
Cancer Genetics to Promote FHACT(TM) Test for Cervical Cancer at American Congress of Obstetricians and Gynecologists' Annual Clinical Meeting
GlobeNewswire - Fri Apr 25, 9:42AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based cancer diagnostics, will be participating in the Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG), being held April 26-30 at the McCormick Place Convention Center in Chicago, Illinois. ACOG is the premier gynecological conference in the U.S. The conference hosts more than 200 exhibitors, and features more than 400 original research posters and paper abstracts. Pathway Genomics Adds Leading Genetic Counselors to Advisory Board
Business Wire - Thu Apr 17, 7:01AM CDT
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that it has added industry-leading genetic counselors Jill Davies, M.S., CCGC, and Elissa Levin, M.S., CGC, to its genetic advisory board.
Bio-Reference Laboratories, Inc. Announces That Robert Daber, Ph.D. Will Join Company as Director of R&D and Cancer Genetics
GlobeNewswire - Wed Apr 16, 7:30AM CDT
Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announced today that it has hired Robert Daber, Ph.D. to assume the dual role as Director of Research and Development and Director of Cancer Genetics at its Elmwood Park international headquarters. BRLI has been an industry leader in clinical diagnostics primarily as a result of its ongoing development of innovative testing based on new and emerging technology. Dr. Daber will take over leadership of this pioneering process along with his directorship of the cancer genetics program at BRLI.
Invitae's Multi-Gene Panels Can Provide Clinical Benefit to Patients Seeking Hereditary Cancer Risk Assessment
Business Wire - Mon Apr 14, 3:00PM CDT
Invitae Corporation, a genetic information company, today announced the publication of initial data from its research collaboration with Stanford University in the Journal of Clinical Oncology, published online on April 14. The study demonstrates that multi-gene hereditary cancer panels can offer comparable performance to traditional BRCA1/2 genetic testing and can provide additional clinical benefit to doctors and patients seeking cancer risk assessment.
Cancer Genetics CEO Moderates Panel Discussion With Thought Leaders in Biopharma at the BioNJ 2014 International BioPartnering Conference
GlobeNewswire - Thu Apr 10, 7:00AM CDT
-- Panna Sharma, CEO of Cancer Genetics, Is Moderating a Panel Entitled "Partnering for a Balanced Portfolio: Perspectives from Innovators, Partners, & Payers"
Cancer Genetics Announces Launch of CALR Mutation Analysis Test to Assist in Diagnosis of Acute Leukemias & Myeloproliferative Neoplasms
GlobeNewswire - Fri Apr 04, 7:17AM CDT
-- New Test Launch Extends CGI's Leadership in Genomic Testing for Blood Cancers
LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc.
Marketwire - Tue Apr 01, 8:03AM CDT
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company developing genomic-based oncology tests and services to enhance disease management and patient outcomes. The Company offers a wide-range of proprietary and non-proprietary tests to support patients during all aspects of their care, from initial diagnosis to prognosis, and determination of optimal treatment options. Oncology is moving towards categorizing cancers by their molecular signature rather than the location in the body, and there is a continuing need for wider access to diagnostic toolkits. Cancer Genetics collaborates with leading research institutions for biomarker development, with community hospitals to improve patient care, and with biotechnology and pharmaceutical companies to provide clinical trial services.
Five Star Quality Care (FVE) in Focus: Stock Tumbles 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:40AM CDT
Five Star Quality Care saw a big move last session, as the company’s shares fell nearly 10% on the day
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Mar 27, 9:56AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature emerging growth companies on Fox Business nationwide on Thursday, March 27, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, March 29, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, March 30, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 30, 2014 at 3:30 p.m. HKT. Cancer Genetics, Inc. Announces Fourth Quarter and Year-End 2013 Results, Provides Corporate Update
GlobeNewswire - Wed Mar 26, 3:01PM CDT
-- 72% Year-Over-Year Revenue Growth During Fourth Quarter 2013
Cancer Genetics to Report Fourth Quarter and Year-End 2013 Results on Wednesday, March 26, 2014
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based diagnostics, announced today that it will report its results for the fourth quarter and year-end 2013 after the market close on Wednesday, March 26, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific. Cancer Genetics Appoints Edward J. Sitar as Chief Financial Officer
GlobeNewswire - Mon Mar 17, 7:08AM CDT
Cancer Genetics (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, announced today that effective April 1, 2014, it has appointed Edward J. Sitar, CPA as Chief Financial Officer. Mr. Sitar will be responsible for all Corporate Finance and Accounting activities for Cancer Genetics.
Cancer Genetics Announces Compelling Diagnostic Sensitivity (99%) and Accuracy (93%) for Its Patent-Protected Genomic Kidney Cancer Test
GlobeNewswire - Wed Mar 05, 7:01AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI"
announced today the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required. BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
Cancer Genetics, Inc. Adds Additional Kidney Cancer Patent to its Portfolio
GlobeNewswire - Wed Feb 26, 6:30AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based diagnostics, today announced that the United States Patent and Trademark Office (USPTO) has allowed its patent claims related to the Company's proprietary methods for detecting the subtype of renal cortical neoplasm present in a patient sample. The patent application (14/078,726) is expected to obtain an issued patent number during the second quarter of 2014. Cancer Genetics, Inc. Announces a New Breakthrough for Diagnosis and Prediction of Kidney Cancer Outcomes Using Its Proprietary Genomic Test
GlobeNewswire - Mon Feb 24, 6:30AM CST
--
Omnicare (OCR) Falls: Stock Goes Down 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:37AM CST
Omnicare Inc. (OCR) saw a big move last session. This stock, trading at a volatile range of $60.68–$64.54 in the past one-month time frame, showed a sharp decline yesterday at $60.98.
